Research at MSK Our research impact Research topics Core facilities & resources ...

Find a researcher or lab Education & training programs MSK Innovation MSK Commercialization Ecosystem ...

If you have questions or concerns, contact your healthcare provider. A member of your care team will answer Monday through Friday from 9 a.m. to 5 p.m. Outside those hours, you can leave a message or ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

To apply for a postdoc position, email your curriculum vitae and bibliography, along with a cover letter describing your background and career objectives, to the head of the research laboratory whose ...

Find a researcher or lab Education & training programs MSK Innovation MSK Commercialization Ecosystem ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Acoustic neuroma — also called vestibular schwannoma — is a type of noncancerous tumor within the skull. It can cause problems with movement, balance, and hearing. Memorial Sloan Kettering experts can ...

DNA replication, repair, and damage response, collectively called the 3Rs, support genome stability and faithful genetic inheritance. Proteins involved in the 3Rs are genome guardians that prevent a ...

Targeting the nectin-4 protein in bladder cancer On a search-and-destroy mission, enfortumab vedotin binds to a protein on cancer cells called nectin-4 and delivers a chemotherapy drug called ...

Thoracic oncologist Kathryn Arbour, MD, led the Phase 1/2 clinical trial of daraxonrasib at MSK for metastatic lung cancer. The drug was approved by the FDA for pancreatic cancer in August 2026 and Dr ...

MSK gastrointestinal medical oncologist Dr. Wungki Park led the early phase clinical trial of daraxonrasib for people with metastatic pancreatic cancer that had stopped responding to chemotherapy.